NCT00030667View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

December 31, 2005

Study Completion Date

December 31, 2005

Conditions
Childhood Desmoplastic Small Round Cell TumorChildhood Synovial SarcomaGastrointestinal Stromal TumorLung MetastasesRecurrent Childhood Soft Tissue SarcomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent Osteosarcoma
Interventions
DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

OTHER

pharmacological study

Correlative studies

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00030667 - Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood | Biotech Hunter | Biotech Hunter